Antibody-drug conjugates (ADCs) consist of linker, payload, and monoclonal antibodies (mAb). They combine the advantages of high specificity targeting ability and potent cytotoxic effects, achieving precise and efficient destruction of cancer cells, making them one of the hot topics in anticancer drug development.Since the first ADC drug Mylotarg® (gemtuzumab ozogamicin) was approved by the FDA … Read more
To build a global highland for the future ADC/RDC industry, Chengdu Medical City plans to hold the first Future XDC New Drug Conference from April 18 to 19, 2024! The conference, themed “Co-creating the Future of the Conjugated Drug Industry,” is organized by Tongxi Yi Planning, featuring a main forum and nine thematic forums. Experts … Read more
Introduction Antibody-drug conjugates (ADC) are formed by linking monoclonal antibodies that target specific antigens with small molecule cytotoxic drugs through linkers, combining the powerful killing effect of traditional small molecule chemotherapy with the tumor targeting ability of antibody drugs. Since the first ADC (Gemtuzumab-ozogamicin (brand name: Mylotarg)) was approved for the treatment of CD33-positive acute … Read more
▲May 2022, Improved New Drug Trends and Technology Conference·Limited TimeFree Registration Ongoing Note:This article does not constitute any investment opinions or advice, subject to official/company announcements;This article is only for the introduction of medical health-related drugs, not a recommendation for treatment plans (if involved), and does not represent the platform’s position.Any article reproduction requires authorization. … Read more
This article is compiled from Professor Song Zhengbo of Zhejiang Provincial Cancer Hospital.“Current Status and Development Challenges of ADC Drugs”. Song Zhengbo Doctor of Oncology, Associate Chief Physician, Associate Professor, Master’s Supervisor More than 100 years ago, the father of immunology, Paul Ehrlich, first proposed the concept of “magic bullet,” which refers to selectively delivering … Read more
1. Overview Antibody-drug conjugates (ADCs) rejuvenate the concept of targeted chemotherapy by coupling cytotoxic payloads to antibodies. The first stage of the complex intracellular toxin delivery process of ADCs is endocytosis. Analyzing the endocytic action of target receptors and ADCs can greatly advance preclinical research, clinical translation, and patient treatment outcomes. The in vitro efficacy … Read more
Since the first ADC drug Mylotarg® (gemtuzumab ozogamicin) was approved by the FDA in 2000, as of December 2021, a total of 14 ADC drugs have been approved globally for hematological malignancies and solid tumors, and currently, there are over 100 ADC candidates at various stages of clinical trials. Recently, the journal Signal Transduction and … Read more
ADCs are currently the trending molecules, sweeping across the globe, with 15 ADC drugs approved for market entry worldwide, and hundreds more under development. Various BD transactions continuously stimulate interest, and these phenomena precisely illustrate the future prospects of ADCs. BD Overview According to incomplete statistics, in the first quarter of 2024, there were 10 … Read more
Introduction Antibody-drug conjugates (ADC) are formed by linking monoclonal antibodies that target specific antigens to small-molecule cytotoxic drugs through linkers, combining the powerful killing effects of traditional small-molecule chemotherapy with the tumor-targeting properties of antibody drugs. Since the first ADC (Gemtuzumab-ozogamicin (brand name: Mylotarg)) was approved for the treatment of CD33-positive acute myeloid leukemia, dozens … Read more
Introduction Degradation-Antibody Conjugates (DACs) are a new type of entity that effectively combines the protein hydrolysis-targeting chimeric (PROTAC) payload with monoclonal antibodies through some type of chemical linker (DAC =PROTAC + ADC). This article collects several examples of DACs from scientific and patent literature and documents specific challenges associated with DAC construction. Overall, these examples … Read more